Skin toxicities of targeted therapies

European Journal of Cancer

Volumn 45, Issue SUPPL. 1, 2009, Pages 295-308

  Segaert, Siegfried ^a   Chiritescu, Gabriela ^a   Lemmens, Liesbeth ^a   Dumon, Kristien ^a   Van Cutsem, Eric ^a   Tejpar, Sabine ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; BENZOYL PEROXIDE; CANERTINIB; CETIRIZINE; CETUXIMAB; CLINDAMYCIN; CORTICOSTEROID; DOXYCYCLINE; ERLOTINIB; ERYTHROMYCIN; FLUCLOXACILLIN; GEFITINIB; HYDROCORTISONE; HYDROXYZINE; LAPATINIB; LORATADINE; LYMECYCLINE; MENADIONE; METRONIDAZOLE; MINOCYCLINE; PANITUMUMAB; PIMECROLIMUS; ROZEX; STEROID; SUNSCREEN; TACROLIMUS; TAZAROTENE; TETRACYCLINE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB;

ACNE; ARTICLE; BREAST CANCER; CLINICAL TRIAL; COLORECTAL CANCER; CREAM; DERMATITIS; DISEASE CLASSIFICATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; ECZEMA; ELECTROCOAGULATION; ERYTHEMA; HAIR; HAIR DISEASE; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; HYPERPIGMENTATION; LOW LEVEL LASER THERAPY; LUNG NON SMALL CELL CANCER; LUPUS LIKE SYNDROME; MONOTHERAPY; MUCOSAL DISEASE; MULTIPLE CYCLE TREATMENT; NAIL; NAIL DISEASE; NOMENCLATURE; PANCREAS CANCER; PARONYCHIA; PATHOPHYSIOLOGY; PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; RADIATION DERMATITIS; RASH; ROSACEA; SIDE EFFECT; SKIN FISSURE; SKIN IRRITATION; STAPHYLOCOCCUS AUREUS; SUPERINFECTION; TELANGIECTASIA; TOXIC HEPATITIS; TREATMENT INDICATION; TREATMENT WITHDRAWAL;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ERUPTIONS; ENZYME INHIBITORS; HUMANS; NEOPLASMS; PHOSPHOTRANSFERASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TELANGIECTASIS; TERMINOLOGY AS TOPIC; TREATMENT OUTCOME;

EID: 70349091806     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(09)70044-9     Document Type: Article

References (66)

1. Johnston J.B., Navaratnam S., Pitz M.W., et al. Targeting the EGFR pathway for cancer therapy. Curr Med Chem 13 (2006) 3483-3492
2. Green M.R., and Couchman J.R. Differences in human skin between the epidermal growth factor receptor distribution detected by EGF binding and monoclonal antibody recognition. J Invest Dermatol 85 (1985) 239-245
3. Busam K.J., Capodieci P., Motzer R., Kiehn T., Phelan D., and Halpern A.C. Cutaneous side-effects in patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144 (2001) 1169-1176
4. Segaert S., and Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16 (2005) 1425-1433
5. Lacouture M.E. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6 (2006) 803-812
6. Galimont-Collen A.F., Vos L.E., Lavrijsen A.P., Ouwerkerk J., and Gelderblom H. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer 43 (2007) 845-851
7. Hu J.C., Sadeghi P., Pinter-Brown L.C., Yashar S., and Chiu M.W. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 56 (2007) 317-326
8. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
9. Van Doorn R., Kirtschig G., Scheffer E., Stoof T.J., and Giaccone G. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 147 (2002) 598-601
10. Walon L., Gibeau C., and Lachapelle J.M. Eruptions acnéiformes induites par le cétuximab. Ann Dermatol Venereol 130 (2003) 443-446
11. Jacot W., Bessis D., Jorda E., et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 151 (2004) 238-241
12. Lee M.W., Seo C.W., Kim S.W., et al. Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Derm Venereol 84 (2004) 23-26
13. Roé E., Garcia Muret M.P., Marcuello E., Capdevila J., Pallarés C., and Alomar A. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. J Am Acad Dermatol 54 (2006) 429-437
14. Van Cutsem E. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Oncologist 11 (2006) 1010-1017
15. Grenader T., Gipps M., and Goldberg A. Staphylocococcus aureus bacteremia secondary to severe erlotinib skin toxicity. Clin Lung Cancer 9 (2008) 59-60
16. Luu M., Lai S.E., Patel J., Guitart J., and Lacouture M.E. Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib. Photodermatol Photoimmunol Photomed 23 (2007) 42-45
17. Bossi P., Liberatoscioli C., Bergamini C., et al. Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients. Ann Oncol 18 (2007) 601-602
18. Tejwani A., Wu S., Jia Y., Agulnik M., Millender L., and Lacouture M.E. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. Cancer 115 (2009) 1286-1299
19. Plewig G., and Kligman A.M. Acne and rosacea. third edition (2000), Springer-Verlag, Berlin
20. Robert C., Soria J.C., Spatz A., et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6 (2005) 491-500
21. http://ctep.cancer.gov/reporting/ctc.html
22. http://ctep.cancer.gov/forms/CTCAEv3.pdf
23. Wollenberg A Moosmann N., Klein E., and Katzer K. A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition. Exp Dermatol 17 (2008) 790-792
24. Chang G.C., Yang T.Y., Chen K.C., Yin M.C., Wang R.C., and Lin Y.C. Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22 (2004) 4646-4648
25. Fox L.P. Nail toxicity associated with epidermal growth factor receptor inhibitor therapy. J Am Acad Dermatol 56 (2007) 460-465
26. Baran R. Etretinate and the nails (study of 130 cases): possible mechanisms of some side-effects. Clin Exp Dermatol 11 (1986) 148-152
27. Dueland S., Sauer T., Lund-Johansen F., Ostenstad B., and Tveit K.M. Epidermal growth factor receptor inhibition induces trichomegaly. Acta Oncol 42 (2003) 345-346
28. Melichar B., and Nemcova I. Eye complications of cetuximab therapy. Eur J Cancer Care 16 (2007) 439-443
29. Scope A., Agero A.L., Dusza S.W., et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 25 (2007) 5390-5396
30. Jatoi A., Rowland K., Sloan J.A., et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes. Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 113 (2008) 847-853
31. Guillot B., and Bessis D. Aspects cliniques et prise en charge des effets secondaires cutanés des inhibiteurs du récepteur à l'EGF. Ann Dermatol Venereol 133 (2006) 1017-1020
32. Gutzmer R., Werfel T., Kapp A., and Elsner J. Kutane Nebenwirkungen einer EGF-Receptor-Blockade und deren management. Hautarzt 57 (2006) 509-513
33. Monti M., and Motta S. Clinical management of cutaneous toxicity of anti-EGFR-agents. Int J Biol Markers 22 (2007) S53-S61
34. Segaert S., Tabernero J., Chosidow O., et al. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges 3 (2005) 599-606
35. Perez-Soler R., Delord J.P., Halpern A., et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 10 (2005) 345-356
36. Lynch T.J., Kim E.S., Eaby B., Garey J., West D.P., and Lacouture M.E. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 12 (2007) 610-621
37. Segaert S., and Van Cutsem E. Clinical management of EGFRI dermatologic toxicities: the Europe perspective. Oncology 5 Suppl 11 (2007) 22-26
38. Segaert S. Management of skin toxicity of epidermal growth factor receptor inhibitors. Targ Oncology 3 (2009) 245-251
39. Bernier J., Bonner J., Vermorken J., et al. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 19 (2008) 142-149
40. Lacouture M.E., Basti S., Patel J., and Benson III A. The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors. J Support Oncol 4 (2006) 236-238
41. Perez-Soler R. Topical vitamin K3 (menadione) prevents erlotinib and cetuximab-induced EGFR inhibition in the skin (abstract). ASCO Annual Meeting Proceedings Part 1. J Clin Oncol 24 (2006) 3036
42. Shu K.-Y., Kindler H.L., Medecina M., and Lacouture M. Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab. Br J Dermatol 154 (2006) 191-192
43. Perez-Soler R., and Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?. J Clin Oncol 23 22 (2005) 5235-5246
44. Saltz L.B., Kies M.S., Abbruzzese J.L., Azarnia N., and Needle M. The presence and intensity of the cetuximab induced acne-like rash predicts survival in studies across multiple malignacies. Proc Am Soc Clin Oncol 24 204 (2003) Abstr 817.
45. Jonker D.J., O'Callaghan C.J., Karapetis C.S., et al. Cetuximab for the treatment of colorectal cancer. [See comment.]. New Engl J Med 357 20 (2007) 2040-2048
46. Lenz H.J., Van Cutsem E., Khambata-Ford S., et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 24 30 (2006) 4914-4921
47. O'Callaghan C.J., Tu D., Karapetis C.S., et al. The relationship between the development of rash and clinical and quality of life outcomes in colorectal cancer patients treated with cetuximab in NCIC CTG CO.17. J Clin Oncol 26 (2008) (May 20 suppl), abstr 4130.
48. Rougier R., Stroiakovski D., Kohne C., et al. Cetuximab and FOLFIRI in first-line metastatic colorectal cancer (mCRC): Updated survival data and influence of KRAS status on outcome in the CRYSTAL study. Gastrointestinal Cancers Symposium, ASCO (2009) Abstr 443.
49. Van Cutsem E., Köhne C.H., Hitre E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360 14 (2009) 1408-1417
50. Agulnik M., da Cunha S.G., Hedley D., et al. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol 25 16 (2007) 2184-2190
51. Tejpar S., Peeters M., Humblet Y., et al. Dose-escalation study using up to twice the standard dose of cetuximab in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST study): Preliminary data. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 24 (2006) 18S [June 20 Suppl]), 3554.
52. Sangha R.S., Ho C., Beckett L., et al. Rash severity and dose in phase I dose escalation cetuximab (C225) trial. J Clin Oncol 26 May 20 suppl (2008) abstr 14573.
53. Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. [See comment.]. J Clin Oncol 25 13 (2007) 1658-1664
54. Van Cutsem E., Siena S., Humblet Y., et al. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 1 (2008) 92-98
55. Berlin J., Van Cutsem E., Peeters M., et al. Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): A pooled analysis of five clinical trials. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25 18S (2007) 4134 [June 20 Suppl])
56. Weiner L.M., Belldegrun A.S., Crawford J., et al. Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res 14 2 (2008) 502-508
57. Clark G.M., Perez-Soler R., Siu L.L., Gordon A.N., and Santabarbara P. Rash severity is predictive of increased survival with erlotinib HCl. Proc Am Soc Clin Oncol 22 (2003) abstr 786.
58. Van Cutsem E., Vervenne W.L., Bennouna J., et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27 13 (2009 May 1) 2231-2237 Epub 2009 Mar 23.
59. Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Cosaert J. Rash as a marker for the efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: Results from the AViTA study. In: Proceedings Gastrointestinal Cancers Symposium, ASCO GI, Orlando 2009; 118 (117) - www.asco.org
60. Agero A.L., Dusza S.W., Benvenuto-Andrade C., Busam K.J., Myskowski P., and Halpern A.C. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 55 (2006) 657-670
61. Heidary N., Naik H., and Burgin S. Chemotherapeutic agents and the skin: an update. J Am Acad Dermatol 58 (2008) 545-570
62. Lacouture M.E., Reilly L.M., Gerami P., and Guitart J. Hand-foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 19 (2008) 1955-1961
63. Robert C., Mateus C., Spatz A., Wechsler J., and Escudier B. Dermatologic symptoms associated with the multikinase-inhibitor sorafenib. J Am Acad Dermatol 60 (2009) 299-305
64. Yang C.H., Lin W.C., Chuang J.K., et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 158 (2008) 592-596
65. Lacouture M.E., Wu S., Robert C., et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 13 (2008) 1001-1011
66. Valeyrie L., Bastuji-Garin S., Revuz J., et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. JAm Acad Dermatol 48 (2003) 201-206